Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12

Patrizia Nanni, Giordano Nicoletti, Carla De Giovanni, Lorena Landuzzi, Emma Di Carlo, Manuela Iezzi, Cinzia Ricci, Annalisa Astolfi, Stefania Croci, Francesco Marangoni, Piero Musiani, Guido Forni, Pier Luigi Lollini

Research output: Contribution to journalArticle

Abstract

FVB-NeuN (N#202) female mice transgenic for the HER-2/neu protooncogene driven by the murine mammary tumor virus (MMTV) promoter develop mammary carcinomas with a progression from focal atypical hyperplasia to in situ carcinoma and to invasive carcinoma that closely resembles that of human neoplasia. Here we report that the combination of tamoxifen plus interleukin 12 (IL-12) results in a very effective prevention of mammary carcinogenesis, significantly higher than those obtained with either tamoxifen or IL-12 alone. At I year of age, 20% of control mice resulted tumor-free, whereas 80% of mice receiving the combined treatment were tumor-free. At 2 years of age, less than 5% of control mice were tumor-free, as opposed to 70% of mice treated with tamoxifen plus IL-12. The combined treatment inhibited mammary carcinogenesis mainly through a reduction in the number of mammary cells at risk of progression, a reduction in estrogen receptors (ERs) expression and a reduction in the angiogenic support to mammary development, likely due to cross-talk between tamoxifen and interferony (IFNy) (the main downstream mediator elicited in vivo by IL-12). The addition of IL-12 to the tamoxifen treatment more than doubled mouse lifetime and did not exacerbate known side effects of tamoxifen.

Original languageEnglish
Pages (from-to)384-389
Number of pages6
JournalInternational Journal of Cancer
Volume105
Issue number3
DOIs
Publication statusPublished - Jun 20 2003

Fingerprint

Tamoxifen
Interleukin-12
Breast Neoplasms
Breast
Neoplasms
Carcinogenesis
Gammaretrovirus
Carcinoma in Situ
Estrogen Receptors
Carcinogens
Transgenic Mice
Hyperplasia
Cell Count
Carcinoma

Keywords

  • Chemoimmunoprevention
  • HER-2/neu
  • Interleukin 12
  • Mammary carcinoma
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. / Nanni, Patrizia; Nicoletti, Giordano; De Giovanni, Carla; Landuzzi, Lorena; Di Carlo, Emma; Iezzi, Manuela; Ricci, Cinzia; Astolfi, Annalisa; Croci, Stefania; Marangoni, Francesco; Musiani, Piero; Forni, Guido; Lollini, Pier Luigi.

In: International Journal of Cancer, Vol. 105, No. 3, 20.06.2003, p. 384-389.

Research output: Contribution to journalArticle

Nanni, P, Nicoletti, G, De Giovanni, C, Landuzzi, L, Di Carlo, E, Iezzi, M, Ricci, C, Astolfi, A, Croci, S, Marangoni, F, Musiani, P, Forni, G & Lollini, PL 2003, 'Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12', International Journal of Cancer, vol. 105, no. 3, pp. 384-389. https://doi.org/10.1002/ijc.11092
Nanni, Patrizia ; Nicoletti, Giordano ; De Giovanni, Carla ; Landuzzi, Lorena ; Di Carlo, Emma ; Iezzi, Manuela ; Ricci, Cinzia ; Astolfi, Annalisa ; Croci, Stefania ; Marangoni, Francesco ; Musiani, Piero ; Forni, Guido ; Lollini, Pier Luigi. / Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. In: International Journal of Cancer. 2003 ; Vol. 105, No. 3. pp. 384-389.
@article{6794a50237df4f16b023707d12dbe3d5,
title = "Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12",
abstract = "FVB-NeuN (N#202) female mice transgenic for the HER-2/neu protooncogene driven by the murine mammary tumor virus (MMTV) promoter develop mammary carcinomas with a progression from focal atypical hyperplasia to in situ carcinoma and to invasive carcinoma that closely resembles that of human neoplasia. Here we report that the combination of tamoxifen plus interleukin 12 (IL-12) results in a very effective prevention of mammary carcinogenesis, significantly higher than those obtained with either tamoxifen or IL-12 alone. At I year of age, 20{\%} of control mice resulted tumor-free, whereas 80{\%} of mice receiving the combined treatment were tumor-free. At 2 years of age, less than 5{\%} of control mice were tumor-free, as opposed to 70{\%} of mice treated with tamoxifen plus IL-12. The combined treatment inhibited mammary carcinogenesis mainly through a reduction in the number of mammary cells at risk of progression, a reduction in estrogen receptors (ERs) expression and a reduction in the angiogenic support to mammary development, likely due to cross-talk between tamoxifen and interferony (IFNy) (the main downstream mediator elicited in vivo by IL-12). The addition of IL-12 to the tamoxifen treatment more than doubled mouse lifetime and did not exacerbate known side effects of tamoxifen.",
keywords = "Chemoimmunoprevention, HER-2/neu, Interleukin 12, Mammary carcinoma, Tamoxifen",
author = "Patrizia Nanni and Giordano Nicoletti and {De Giovanni}, Carla and Lorena Landuzzi and {Di Carlo}, Emma and Manuela Iezzi and Cinzia Ricci and Annalisa Astolfi and Stefania Croci and Francesco Marangoni and Piero Musiani and Guido Forni and Lollini, {Pier Luigi}",
year = "2003",
month = "6",
day = "20",
doi = "10.1002/ijc.11092",
language = "English",
volume = "105",
pages = "384--389",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12

AU - Nanni, Patrizia

AU - Nicoletti, Giordano

AU - De Giovanni, Carla

AU - Landuzzi, Lorena

AU - Di Carlo, Emma

AU - Iezzi, Manuela

AU - Ricci, Cinzia

AU - Astolfi, Annalisa

AU - Croci, Stefania

AU - Marangoni, Francesco

AU - Musiani, Piero

AU - Forni, Guido

AU - Lollini, Pier Luigi

PY - 2003/6/20

Y1 - 2003/6/20

N2 - FVB-NeuN (N#202) female mice transgenic for the HER-2/neu protooncogene driven by the murine mammary tumor virus (MMTV) promoter develop mammary carcinomas with a progression from focal atypical hyperplasia to in situ carcinoma and to invasive carcinoma that closely resembles that of human neoplasia. Here we report that the combination of tamoxifen plus interleukin 12 (IL-12) results in a very effective prevention of mammary carcinogenesis, significantly higher than those obtained with either tamoxifen or IL-12 alone. At I year of age, 20% of control mice resulted tumor-free, whereas 80% of mice receiving the combined treatment were tumor-free. At 2 years of age, less than 5% of control mice were tumor-free, as opposed to 70% of mice treated with tamoxifen plus IL-12. The combined treatment inhibited mammary carcinogenesis mainly through a reduction in the number of mammary cells at risk of progression, a reduction in estrogen receptors (ERs) expression and a reduction in the angiogenic support to mammary development, likely due to cross-talk between tamoxifen and interferony (IFNy) (the main downstream mediator elicited in vivo by IL-12). The addition of IL-12 to the tamoxifen treatment more than doubled mouse lifetime and did not exacerbate known side effects of tamoxifen.

AB - FVB-NeuN (N#202) female mice transgenic for the HER-2/neu protooncogene driven by the murine mammary tumor virus (MMTV) promoter develop mammary carcinomas with a progression from focal atypical hyperplasia to in situ carcinoma and to invasive carcinoma that closely resembles that of human neoplasia. Here we report that the combination of tamoxifen plus interleukin 12 (IL-12) results in a very effective prevention of mammary carcinogenesis, significantly higher than those obtained with either tamoxifen or IL-12 alone. At I year of age, 20% of control mice resulted tumor-free, whereas 80% of mice receiving the combined treatment were tumor-free. At 2 years of age, less than 5% of control mice were tumor-free, as opposed to 70% of mice treated with tamoxifen plus IL-12. The combined treatment inhibited mammary carcinogenesis mainly through a reduction in the number of mammary cells at risk of progression, a reduction in estrogen receptors (ERs) expression and a reduction in the angiogenic support to mammary development, likely due to cross-talk between tamoxifen and interferony (IFNy) (the main downstream mediator elicited in vivo by IL-12). The addition of IL-12 to the tamoxifen treatment more than doubled mouse lifetime and did not exacerbate known side effects of tamoxifen.

KW - Chemoimmunoprevention

KW - HER-2/neu

KW - Interleukin 12

KW - Mammary carcinoma

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0037882102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037882102&partnerID=8YFLogxK

U2 - 10.1002/ijc.11092

DO - 10.1002/ijc.11092

M3 - Article

C2 - 12704673

AN - SCOPUS:0037882102

VL - 105

SP - 384

EP - 389

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -